Belite Bio's DRAGON data head to ASRS as first Phase 3 win in Stargardt disease
Tinlarebant already cut Stargardt lesion growth 35.7% versus placebo in the completed DRAGON trial; the ASRS presentation puts that result before retina specialists for the first time.
Executive Summary
- Belite Bio's Phase 3 trial of tinlarebant in adolescent Stargardt disease met its primary endpoint, slowing the retinal lesion growth that drives vision loss in this inherited disease.
- The upcoming presentation puts the full dataset, including secondary endpoints and safety, in front of retina specialists for the first time, beyond the topline figure the company already disclosed.
- No treatment is approved for Stargardt disease, and no other RBP4-targeting or small-molecule mechanism has produced a positive Phase 3 result in this population, which makes this the first mechanism to clear that bar.
- Enrollment and timeline changes during the trial's four-year run were within the range regulators and investors typically tolerate for a rare pediatric disease study, so execution is not the open question; how the secondary visual-acuity and safety data read is.
The disclosure ahead of the talk
Belite Bio said in a March 2, 2026 disclosure that the DRAGON trial (NCT05244304) met its primary endpoint, showing a 35.7% reduction in the growth of atrophic lesions, measured by definitely decreased autofluorescence (DDAF) on fundus autofluorescence photography, versus placebo over 24 months, with a p-value of 0.0033. The ASRS session on July 18 will present those results in full to a clinical audience for the first time, delivered by Paul Bernstein, M.D., Ph.D. of the Moran Eye Center at the University of Utah. A second presentation covering the same topline data ran at the ISCEV meeting in Sydney on July 8, 2026. BeliteBelite Bio Announces Oral Presentations at Two Upcoming Medical ConferencesJul 6, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The trial and the disease
DRAGON enrolled 104 adolescents aged 12 to 20 with genetically confirmed Stargardt disease type 1 (STGD1), a mutation in the ABCA4 gene that causes progressive vision loss with no approved treatment. Tinlarebant is an oral drug that lowers serum retinol binding protein 4 (RBP4), the sole carrier that transports vitamin A to the eye, reducing the buildup of toxic byproducts called bisretinoids that drive the retinal damage measured by DDAF. The randomized, placebo-controlled design ran from March 2022 through completion in October 2025, with one experimental arm and one placebo arm across sites in eleven countries. NCT05244304+1Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt DiseaseNCT05244304Belite Bio Announces Oral Presentations at Two Upcoming Medical ConferencesJul 6, 2026
Trial conduct
Enrollment grew from a target of 60 to 90 in May 2023 and then to 104 by November 2023, while the primary completion date moved from December 2024 to March 2025 and then to August 2025. Those adjustments came while the trial was still recruiting or newly active and not recruiting, and the enrollment increase in a registrational trial that ultimately completed on schedule at its most recent guided date reads as normal execution rather than a warning sign. The trial completed cleanly, reaching Completed status in October 2025 with its full target enrolled. NCT05244304Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt DiseaseNCT05244304
The competitive field
No other Phase 3 asset targets RBP4 in Stargardt disease, and the only other trial sharing both the target and the small-molecule modality is Belite Bio's own separate Phase 2/3 study of tinlarebant in a broader Stargardt population (NCT06388083), plus a Phase 2 program from Stargazer Pharmaceuticals (STG-001, NCT04489511). Other Stargardt programs, including Alkeus Pharmaceuticals' oral retinoid-cycle modulators and gene-therapy candidates from Ocugen and AAVantgarde, work through different mechanisms and none has yet produced a positive Phase 3 result in this disease. DRAGON is the first Phase 3 trial in Stargardt disease, across any mechanism, to disclose a primary endpoint met with a p-value below 0.01. BeliteBelite Bio Announces Oral Presentations at Two Upcoming Medical ConferencesJul 6, 2026
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.